枸地氯雷他定联合甘草酸二胺治疗慢性荨麻疹66例临床观察  

Treatment of 66 Cases of Chronic Urticaria with Desloratadine Citrate Plus Diammonium Glycyrrhizinate

作　　者：沈悦[1] 张懿[1] 徐晶[1] 杨平安[1] 刘武林[1] 

机构地区：[1]苏州市立医院北区医学美容及皮肤科,江苏苏州215000

出　　处：《中国皮肤性病学杂志》2017年第8期933-936,共4页The Chinese Journal of Dermatovenereology

摘　　要：目的评价枸地氯雷他定联合甘草酸二胺治疗慢性荨麻疹临床疗效和安全性,并探讨其作用机制。方法将入选的120例慢性荨麻疹患者采用随机数字表法分为两组,治疗组(65例)予枸地氯雷他定治疗组联合甘草酸二胺胶囊治疗,对照组(55例)仅予枸地氯雷他定治疗。疗程结束时比较两组患者的临床疗效和血清细胞因子水平等。结果治疗4周后,治疗组症状体征得分低于对照组(P<0.05),有效率为98.46%,明显高于对照组89.09%(P<0.05)。两组患者恶心、呕吐、肝肾功能受损、口干和嗜睡发生率差异无统计学意义(P>0.05)。治疗4周后,治疗组白介素-6(IL-6),超敏C反应蛋白(hsCRP)和肿瘤坏死因子-α(TNF-α)低于对照组(P<0.05)。结论枸地氯雷他定联合甘草酸二胺治疗慢性荨麻疹疗效显著,且不良反应发生率低,可能与甘草酸二胺可降低外周血细胞因子水平有关。Objective To investigate the efficacy and safety of desloratadine citrate and diammonium glycyrrhizinate for chronic urticaria and its mechanisms. Methods Random number table was used to divide 120 patients with chronic urticaria into the treatment group treated with both desloratadine citrate and diammonium glycyrrhizinate and the control group treated with desloratadine citrate alone. The efficacy and levels of serum cytokines were assessed after the treatment. Results After 4-week treatment, clinical sign and symptom scores were significantly lower in the treatment groups than in the controls （P〈0.05）, while the effective rates were higher in the treatment groups than in the controls（P 〈0.05）. In contrast, the incidences of nausea, vomiting, liver and kidney dysfunction, dry mouth and sleepiness were no differences between the two groups（P〉 0.05）. Moreover, following the treatments, levels of IL-6, high sensitivity C-reactive protein（hs-CRP）and tumor necrosis factor alpha（TNF-α）, were significantly lower in the treatment group in comparison with the controls（P 〈0.05）. Conclusion Combination of desloratadine citrate and diammonium glycyrrhizinate is effective and safe for chronic urticarial, possibly via reductions in levels of serum cytokines induced by diammonium glycyrrhizinate.

关 键 词：枸地氯雷他定 甘草酸二胺 荨麻疹 细胞因子 

分 类 号：R758.24[医药卫生—皮肤病学与性病学]